Chapter Six - The First Deaths

CHAPTER SIX

The First Deaths

THEY DIDN’T COME all at once.

They came like whispers.
A teenager in Kentucky.
A miner in West Virginia.
A mother in Ohio who never woke up.

Each death felt isolated. A personal tragedy, not a public crisis. Overdose was still seen as a back-alley problem, not something that could start in a pharmacy and end in a morgue. But the pattern was there. And it was growing.

Doctors noticed first.

In rural clinics, patients came back too early, asking for refills. Some looked high. Others looked sick. Some were crushing the pills. Others were selling them. Word spread quickly: OxyContin wasn’t just relieving pain. It was hooking people.

Pharmacists raised flags. Nurses sounded alarms. Local coroners filed overdose reports with “oxycodone” listed again and again.

Purdue’s response?

They denied, delayed, and deflected.

When communities begged the company to investigate abuse hotspots, Purdue sent brochures. When internal memos warned of overdose clusters, executives dismissed them as anecdotal. When lawsuits started trickling in from grieving families, the company argued that misuse wasn’t their fault.

Their stance was simple:
We sold a legal product. They used it wrong.

It was a familiar play, shift the blame downstream. But the numbers were climbing too fast to ignore.

By 2001, overdose deaths from prescription opioids had more than doubled since Oxy hit the market. By 2002, Oxy was being called “Hillbilly Heroin” by newspapers across Appalachia. And by 2003, entire towns were holding public meetings about how to stop their children from dying.

Still, Purdue refused to pull the product.
Still, the FDA hesitated.
Still, the pills kept flowing.

The first deaths weren’t just casualties of a drug.
They were early warnings.

Ignored.
Buried.
And repeated by the thousands.

This wasn’t just addiction.
It was a slow-motion massacre.

And the company knew exactly where the trail led.